Regencell Bioscience Holdings Limited [RGC] Securities Class Action Lawsuit Update

• Case Name: Matassa v. Regencell Bioscience Holdings Limited, et al.
• Case No.: 1:26-cv-01602-BAH
• Jurisdiction: United States District Court for the District of Maryland (Northern Division)
• Filed on: April 24, 2026
• Class Period: October 28, 2024 – October 31, 2025, inclusive

Introduction

Regencell Bioscience Holdings Limited (NASDAQ: RGC) said it was building treatments for ADHD and autism using traditional Chinese medicine. Investors allege something else was happening beneath the surface: a dramatic stock surge disconnected from business fundamentals, paired with misleading disclosures about the risks surrounding that volatility.

The securities class action filed against Regencell Bioscience Holdings Limited, along with founder and CEO Yat-Gai Au and Financial Controller Michelle Chan, claims the company failed to disclose that its ordinary shares were vulnerable to market manipulation and that the resulting volatility exposed investors to significant financial risk and regulatory scrutiny. According to the complaint, defendants instead pointed to short squeezes, social media activity, and outside commentary while omitting the deeper problem—an alleged heightened risk of government investigation and enforcement.

The alleged truth emerged when Regencell disclosed that the U.S. Department of Justice had issued correspondence and a subpoena regarding trading in its ordinary shares. The stock fell sharply, and investors followed with litigation.

“Most RGC shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Regencell describes itself as an early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine for attention-deficit/hyperactivity disorder and autism spectrum disorder. The company has publicly stated that while existing treatments merely “suppress or alleviate symptoms,” its own TCM formula aims “to treat the fundamental cause of neurocognitive disorders.”

According to the complaint, Regencell had only twelve employees, no approved or salable products, no revenue, and recurring operating losses since formation. Its research and development spending was approximately $0.95 million for fiscal 2025 and $1.07 million for fiscal 2024, despite the company itself acknowledging that the average cost to bring a new medicine to market can approach $4 billion or more.

The company also operated as a Nasdaq “controlled company.” As of June 30, 2025, directors and executive officers held 88.8% of shares, with founder, Chairman, and CEO Yat-Gai Au owning 88.6% of shares. That level of insider concentration became central to plaintiff allegations regarding scienter and market influence.

Yet despite limited operations and no revenue-producing products, Regencell’s market capitalization reached approximately $14 billion. The complaint notes that even The Wall Street Journal observed that only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value.

That contrast sits at the center of the case.

Promises Made vs. Reality

Regencell’s SEC filings repeatedly warned that its stock “may be highly volatile” and cited general market risks, analyst estimates, exchange rate fluctuations, and negative publicity. The company also warned that a possible “short squeeze” could cause dramatic price movement unrelated to operations.

It told investors: “A short squeeze could lead to volatile price movements in our Ordinary Shares that are not directly correlated to the performance or prospects of our company.”

Later, in interim financial statements, Regencell stated: “The market price of our ordinary shares has been extremely volatile and may continue to be volatile due to numerous circumstances beyond our control.”

The company again emphasized short sellers, third-party blogs, articles, message boards, and social media as likely drivers.

Investors allege those disclosures were incomplete and misleading.

According to the complaint, defendants failed to disclose that Regencell was vulnerable to market manipulation itself, not merely volatility caused by ordinary short activity or speculative trading. Plaintiff alleges the company omitted that this volatility created substantial investor risk and exposed Regencell to a heightened likelihood of DOJ scrutiny, enforcement action, legal costs, fines, reputational damage, and monetary penalties.

In securities litigation, the difference between “market volatility” and “market manipulation” is not semantic. It is often the whole case.

Timeline of Alleged Misconduct and Disclosures

The class period begins on October 28, 2024, after Regencell filed its annual Form 20-F for fiscal 2024. The filing included broad risk disclosures about volatility and potential short squeezes, but plaintiffs argue these were generic warnings that failed to reflect known and existing risks.

For months, Regencell traded below $1 per share. Then the price moved.

May 1, 2025: Regencell shares closed at $2.03. By the end of May, they were trading near $20 per share—an approximate 900% increase in one month.

June 2, 2025: The company announced a 38-for-one forward stock split, stating it was intended “to enhance liquidity in the market for the Company’s ordinary shares and make the shares more accessible to investors.”

June 16, 2025: After split-adjusted trading began, shares closed at $60. The next day, June 17, they closed at a class-period high of $78 per share—a 48,650% increase from the start of the class period. Within days, they fell back toward the low $20 range.

June 30, 2025: Regencell filed a Form 6-K acknowledging “extreme price and volume fluctuations” often unrelated to operating performance. Still, the filing continued to emphasize short squeezes and third-party media activity rather than alleged manipulation risk.

October 31, 2025: Regencell disclosed in its annual filing that it had received DOJ correspondence and a subpoena and that the Department of Justice was investigating trading in its ordinary shares. The company stated the DOJ requested documents concerning trading, operations, financial matters, and accounting issues, and warned it could face fines, penalties, damages, or settlement costs beyond insurance coverage.

That disclosure changed the story.

Investor Harm and Market Reaction

On November 3, 2025, after the DOJ investigation disclosure, Regencell’s ordinary share price fell $3.09 per share, or 18.56%, closing at $13.56. Plaintiff alleges this drop represented the market finally absorbing information defendants should have disclosed earlier.

The complaint ties investor harm to the artificial inflation created by allegedly misleading statements and omissions. Investors who purchased shares during the class period—particularly during the rapid May and June 2025 rise—allegedly bought at prices disconnected from business fundamentals and unsupported by actual operating performance.

The company itself admitted there were no material changes in financial condition or results of operations that explained the extraordinary price volatility. That statement matters. It narrows the possible explanations and strengthens plaintiff arguments around loss causation and material omission.

The complaint also notes continuing volatility even after the class period, citing Bloomberg reports of sharp price spikes in March and April 2026 despite no apparent corresponding business developments. The pattern, investors argue, did not disappear. It simply became harder to ignore.

Litigation and Procedural Posture

Plaintiff Joseph Matassa filed the action individually and on behalf of all others similarly situated in the District of Maryland on April 24, 2026. The proposed class includes all persons and entities that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025.

The complaint asserts claims under:

• Section 10(b) of the Securities Exchange Act of 1934
• Rule 10b-5 promulgated thereunder
• Section 20(a) of the Exchange Act

Defendants include:

• Regencell Bioscience Holdings Limited
• Yat-Gai Au, founder, Chairman, and CEO
• Michelle Chan, Financial Controller

Plaintiff alleges scienter based largely on insider control, knowledge of extreme stock volatility, and the extraordinary transformation of Regencell from a penny-stock company into a business valued at roughly $14 billion despite having minimal operations and no revenue. Defendant Au’s ownership of more than 80% of ordinary shares is cited as evidence that he was “undoubtedly highly attuned” to significant stock price fluctuations.

The complaint also invokes Item 105 and Item 303 of SEC Regulation S-K, arguing defendants failed to disclose known risks and trends related to manipulation vulnerability and resulting legal and financial exposure.

SEC Filings & Risk Factors

The complaint places heavy emphasis on Regencell’s Form 20-F filings and interim Form 6-K disclosures.

In the October 2024 Form 20-F, Regencell warned that its ordinary shares “may be very thinly traded” and that price volatility could result from general market conditions, analyst revisions, publicity, and operational performance. It also specifically highlighted short squeeze risks.

The June 2025 Form 6-K went further, acknowledging “extreme price and volume fluctuations” and specifically noting that between April 26 and June 20, 2025, the stock ranged from $0.832 to $83.600 per share. The company admitted it had not experienced any material business developments that would explain those moves.

Still, plaintiffs argue these disclosures were insufficient because they framed the problem as speculative volatility rather than a known risk of manipulation and resulting government scrutiny.

Under Item 105, plaintiffs allege Regencell was required to disclose the material factors making investment speculative or risky. Under Item 303, it allegedly had to disclose known trends or uncertainties likely to materially affect operations. Plaintiff claims both duties were violated because defendants failed to disclose the company’s alleged vulnerability to manipulation and the foreseeable regulatory fallout.

The October 31, 2025 filing changed that posture. It disclosed the DOJ subpoena, document requests, expected legal costs, and the possibility of fines, penalties, damages, and proceedings against the company or its officers.

How to Join the Regencell Bioscience Holdings Limited (RGC) Class Action

• Confirm you purchased RGC shares during the October 28, 2024 through October 31, 2025 class period
• Review your trading records and eligibility details
• Consult an attorney regarding lead plaintiff deadlines and recovery rights
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.